HRP20180226T1 - Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc - Google Patents

Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc Download PDF

Info

Publication number
HRP20180226T1
HRP20180226T1 HRP20180226TT HRP20180226T HRP20180226T1 HR P20180226 T1 HRP20180226 T1 HR P20180226T1 HR P20180226T T HRP20180226T T HR P20180226TT HR P20180226 T HRP20180226 T HR P20180226T HR P20180226 T1 HRP20180226 T1 HR P20180226T1
Authority
HR
Croatia
Prior art keywords
seq
gram
bacterial cell
negative bacterial
antibody
Prior art date
Application number
HRP20180226TT
Other languages
English (en)
Inventor
Mark Ellis
David Paul Humphreys
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of HRP20180226T1 publication Critical patent/HRP20180226T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90Isomerases (5.)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Claims (15)

1. Rekombinantna gram-negativna bakterijska stanica koja sadrži: a) ekspresijski vektor koji sadrži rekombinantni polinukleotid koji kodira DsbC; i b) jedan ili više polinukleotida koji kodiraju antitijelo ili antigen vezujući fragment od njih koji se specifično veže za CD154; c) mutirani Tsp gen koji kodira Tsp protein koji ima 50% ili manje aktivnosti proteaze divljeg tipa ne-mutiranog Tsp proteina kao što je prikazano u SEK ID BR: 26 i; d) mutirani spr gen koji kodira spr protein čija je sekvenca divljeg tipa prikazana u SEK ID BR: 24 uključujući mutaciju koja utječe na aminokiselinu C94; i pri čemu je navedena gram-negativna bakterijska stanica izabrana od sojeva E. coli K12 i W3110, i pri čemu je bakterijska stanica izogen za navedene sojeve, osim za rekombinantni polinukleotid koji kodira DsbC, jedan ili više polinukleotida koji kodiraju antitijelo ili antigen vezujući fragment od njih koji se specifično veže za CD154 i mutirani Tsp gen i mutirani spr gen.
2. Gram-negativna bakterijska stanica prema patentnom zahtjevu 1, naznačena time da DsbC sadrži histidin–tag na N-terminusu ili C-terminusu.
3. Gram-negativna bakterijska stanica prema patentnom zahtjevu 1 ili 2, naznačena time da ekspresijski vektor sadrži polinukleotid koji ima sekvencu danu u SEK ID BR: 45 ili SEK ID BR: 51.
4. Gram-negativna bakterijska stanica prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time da antitijelo ili antigen vezujući fragment od njih sadrži varijabilnu domenu teškog lanca koja sadrži tri CDR-a koji imaju sekvencu danu u SEK ID BR: 1 za CDRH1, SEK ID BR: 2, za CDRH2 i SEK ID BR: 3 za CDRH3 i varijabilnu domenu lakog lanca koji sadrži tri CDR-a koji imaju sekvencu danu u SEK ID BR: 4 za CDRL1, SEK ID BR: 5 za CDRL2 i SEK ID BR: 6 za CDRL3.
5. Gram-negativna bakterijska stanica prema patentnom zahtjevu 4, naznačena time da jedan ili više polinukleotida kodiraju antitijelo koje sadrži sekvencu varijabilne regije lakog lanca danu u SEK ID BR: 8 i varijabilnu regiju teškog lanca danu u SEK ID BR: 10.
6. Gram-negativna bakterijska stanica prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time da je antitijelo Fab ili Fabov fragment.
7. Gram-negativna bakterijska stanica prema patentnom zahtjevu 6, naznačena time da Fab ili Fabov fragment sadrži laki lanac koji ima sekvencu danu u SEK ID BR: 12 i teški lanac, koji ima sekvencu danu u SEK ID BR: 14 ili 16.
8. Gram-negativna bakterijska stanica prema bilo kojem od patentnih zahtjeva 1 do 7, naznačena time da gram-negativna bakterijska stanica sadrži prvi ekspresijski vektor koji sadrži rekombinantni polinukleotid koji kodira DsbC i drugi ekspresijski vektor koji sadrži jedan ili više polinukleotida koji kodiraju antitijelo ili antigen koji veže fragment od njih, posebno koji veže CD154.
9. Gram-negativna bakterijska stanica prema bilo kojem od patentnih zahtjeva 1 do 7, naznačena time da ekspresijski vektor, koji sadrži rekombinantni polinukleotid koji kodira DsbC, dodatno sadrži jedan ili više polinukleotida koji kodiraju antitijelo ili antigen vezujući fragment od njih, posebno koji veže CD154.
10. Gram-negativna bakterijska stanica prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da mutacija u spr genu koji kodira spr protein, rezultira u promjeni aminokiselinskog cisteina u alanin na poziciji 94 (C94A).
11. Gram-negativna bakterijska stanica prema bilo kojem od patentnih zahtjeva 1 do 10, koji sadrži ekspresijski vektor koji sadrži rekombinantni polinukleotid koji kodira DsbC i dicistronsku poruku za proizvodnju antitijela ili antigen vezujućeg fragmenta od njih, posebno koji veže CD154, u kojem uzvodni cistron sadrži DNA koja kodira laki lanac antitijela i nizvodni cistron sadrži DNA koja kodira odgovarajući teški lanac, naznačena time da dicistronska poruka sadrži sekvencu izabranu od IGS1 (SEK ID BR: 33), IGS2 (SEK ID BR:34), IGS3 (SEK ID BR: 35) i IGS4 (SEK ID BR: 36).
12. Postupak za proizvodnju antitijela ili antigen vezujućeg fragmenta od njih posebno koji veže CD154, naznačen time da sadži: a) kultiviranje rekombinantne gram-negativne bakterijske stanice kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 11 u mediju kulture pod uvjetima efikasnim da eksprimiraju antitijelo ili antigen vezujući fragment od njih, posebno koji veže CD154 i rekombinantni polinukleotid koji kodira DsbC; i b) obnavljanje antitijela ili antigen vezujućeg fragmenta od njih, posebno koji veže CD154 iz periplazme rekombinantne gram-negativne bakterijske stanice i/ili medija kulture.
13. Postupak prema patentnom zahtjevu 12, naznačen time da postupak dalje sadrži korak spajanja efektorske molekule na aminokiselinu na ili prema C-terminalnom kraju teškog lanca i/ili lakog lanca antitijela.
14. Postupak prema patentnom zahtjevu 13, naznačen time da efektorska molekula sadrži poli(etilenglikol) ili metoksipoli(etilenglikol).
15. Postupak prema patentnom zahtjevu 14, naznačen time da postupak sadrži vezanje na jedan od cisteinskih ostataka na C-terminalnom kraju teškog lanca lizil-maleimidne skupine, pri čemu svaka amino skupina lizil ostatka ima kovalentno povezan sa njim metoksipoli(etilenglikol) ostatak koji ima molekulsku težinu od oko 20,000 Da.
HRP20180226TT 2011-07-13 2018-02-06 Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc HRP20180226T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173880 2011-07-13
PCT/EP2012/002945 WO2013007388A1 (en) 2011-07-13 2012-07-13 Bacterial host strain expressing recombinant dsbc
EP12737492.4A EP2731973B1 (en) 2011-07-13 2012-07-13 Bacterial host strain expressing recombinant dsbc

Publications (1)

Publication Number Publication Date
HRP20180226T1 true HRP20180226T1 (hr) 2018-03-09

Family

ID=46545736

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180226TT HRP20180226T1 (hr) 2011-07-13 2018-02-06 Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc

Country Status (27)

Country Link
US (2) US9725516B2 (hr)
EP (2) EP2731973B1 (hr)
JP (3) JP6431370B2 (hr)
KR (1) KR102023786B1 (hr)
CN (1) CN103649124B (hr)
AU (1) AU2012283388B2 (hr)
BR (1) BR112013032871B1 (hr)
CA (1) CA2841824C (hr)
CY (1) CY1119985T1 (hr)
DK (1) DK2731973T3 (hr)
EA (1) EA031449B1 (hr)
ES (1) ES2659155T3 (hr)
HK (1) HK1194393A1 (hr)
HR (1) HRP20180226T1 (hr)
HU (1) HUE035674T2 (hr)
IL (1) IL229947B (hr)
IN (1) IN2014DN00202A (hr)
LT (1) LT2731973T (hr)
ME (1) ME02957B (hr)
MX (1) MX348738B (hr)
NO (1) NO2731973T3 (hr)
PL (1) PL2731973T3 (hr)
PT (1) PT2731973T (hr)
RS (1) RS56926B1 (hr)
SG (1) SG10201807560XA (hr)
SI (1) SI2731973T1 (hr)
WO (1) WO2013007388A1 (hr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009010120A (es) * 2007-03-22 2009-10-19 Ucb Pharma Sa Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
HUE040306T2 (hu) 2009-09-24 2019-03-28 Ucb Biopharma Sprl Baktériumtörzs rekombináns fehérje expresszálására, amely tartalmaz proteázhiányos, de chaperonaktivitását megtartott DEGP-t és génkiütött TSP és PTR gént
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
HUE035674T2 (en) * 2011-07-13 2018-05-28 Ucb Biopharma Sprl Bacterial host strains expressing recombinant DSBC
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
EP4253548A3 (en) 2014-12-22 2024-01-03 UCB Biopharma SRL Protein manufacture
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
AU2017212484C1 (en) 2016-01-27 2020-11-05 Medimmune, Llc Methods for preparing antibodies with a defined glycosylation pattern
EP3877407A1 (en) * 2018-11-05 2021-09-15 F. Hoffmann-La Roche AG Methods of producing two chain proteins in prokaryotic host cells
CN109371049A (zh) * 2018-11-14 2019-02-22 天津大学 分子伴侣在促进单克隆抗体的形成和/或提高单克隆抗体的表达量中的应用
EP3942079A1 (en) 2019-03-18 2022-01-26 Bio-Rad ABD Serotec GmbH Protection of spytag-containing periplasmic fusion proteins from protease tsp and ompt degradation
WO2021023367A1 (de) * 2019-08-05 2021-02-11 Wacker Chemie Ag Bakterienstamm zur freisetzung eines rekombinanten proteins in einem fermentationsverfahren

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
AU4118393A (en) 1992-04-28 1993-11-29 Regents Of The University Of Michigan, The Human crabp-I and crabp-II
GB9215540D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US5304472A (en) 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
JP2000083670A (ja) 1998-09-09 2000-03-28 Hsp Kenkyusho:Kk DsbA/DsbB/DsbC/DsbD発現プラスミド
JP2003503074A (ja) 1999-06-29 2003-01-28 シガ・テクノロジーズ,インコーポレイテッド Degpプロテアーゼインヒビター類の分析方法
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
AU2001287040A1 (en) 2000-09-01 2002-03-13 Biogen, Inc. Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins
US7041479B2 (en) 2000-09-06 2006-05-09 The Board Of Trustess Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
ATE318890T1 (de) 2000-12-14 2006-03-15 Genentech Inc Bakterielle wirtstämme
ATE405650T1 (de) 2000-12-14 2008-09-15 Genentech Inc Produktion von ganzen antikörpern in prokaryontischen zellen
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
NZ530852A (en) * 2001-08-27 2006-11-30 Genentech Inc Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
JP2005535282A (ja) 2001-11-16 2005-11-24 アイデック ファーマシューティカルズ コーポレイション 抗体のポリシストロニック発現
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
CA2528551A1 (en) 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
ATE414106T1 (de) 2003-06-30 2008-11-15 Domantis Ltd Pegylierte single-domain-antikörper (dab)
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2533593A1 (en) 2003-07-26 2005-02-10 Biogen Idec Ma Inc. Altered antibodies having improved antigen-binding affinity
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
JP2008511337A (ja) * 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0425534D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
GB0520169D0 (en) 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
MX2009010120A (es) 2007-03-22 2009-10-19 Ucb Pharma Sa Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
EP2195341B1 (en) 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
US7662587B1 (en) 2009-03-05 2010-02-16 E. I. Du Pont De Nemours And Company Gene knockout mutations that increase peptide production
HUE040306T2 (hu) 2009-09-24 2019-03-28 Ucb Biopharma Sprl Baktériumtörzs rekombináns fehérje expresszálására, amely tartalmaz proteázhiányos, de chaperonaktivitását megtartott DEGP-t és génkiütött TSP és PTR gént
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
AU2010314981B2 (en) * 2009-11-05 2015-07-02 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
GB201000591D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
HUE035674T2 (en) 2011-07-13 2018-05-28 Ucb Biopharma Sprl Bacterial host strains expressing recombinant DSBC
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product

Also Published As

Publication number Publication date
EP2731973B1 (en) 2017-11-15
EP2731973A1 (en) 2014-05-21
CY1119985T1 (el) 2018-12-12
HK1194393A1 (zh) 2014-10-17
SI2731973T1 (en) 2018-04-30
CN103649124B (zh) 2016-04-13
US9957328B2 (en) 2018-05-01
US20140141468A1 (en) 2014-05-22
CA2841824C (en) 2021-07-13
JP2020028299A (ja) 2020-02-27
JP6431370B2 (ja) 2018-11-28
LT2731973T (lt) 2018-02-26
JP2018019719A (ja) 2018-02-08
BR112013032871A2 (pt) 2017-01-24
MX2014000302A (es) 2014-02-17
RS56926B1 (sr) 2018-05-31
PT2731973T (pt) 2018-02-22
AU2012283388B2 (en) 2017-04-20
IL229947B (en) 2019-10-31
NO2731973T3 (hr) 2018-04-14
JP7062626B2 (ja) 2022-05-17
ES2659155T3 (es) 2018-03-14
EA201490274A1 (ru) 2014-05-30
AU2012283388A1 (en) 2014-01-09
CN103649124A (zh) 2014-03-19
EP3339325A1 (en) 2018-06-27
KR20140039240A (ko) 2014-04-01
BR112013032871A8 (pt) 2022-08-23
SG10201807560XA (en) 2018-10-30
PL2731973T3 (pl) 2018-04-30
MX348738B (es) 2017-06-27
CA2841824A1 (en) 2013-01-17
IN2014DN00202A (hr) 2015-06-05
DK2731973T3 (da) 2018-01-29
WO2013007388A1 (en) 2013-01-17
EA031449B1 (ru) 2019-01-31
HUE035674T2 (en) 2018-05-28
KR102023786B1 (ko) 2019-09-20
ME02957B (me) 2018-07-20
US9725516B2 (en) 2017-08-08
BR112013032871B1 (pt) 2022-09-27
JP2014521313A (ja) 2014-08-28
US20170335003A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
HRP20180226T1 (hr) Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc
JP2021020905A5 (hr)
JP2018085988A5 (hr)
JP2014521313A5 (hr)
HRP20190897T1 (hr) Laki lanac humaniziranih miševa
TWI713942B (zh) 與集落刺激因子1受體(csf1r)結合之抗體類
ES2649098T3 (es) Anticuerpos de unión a albumina y fragmentos de unión de los mismos
RU2013148919A (ru) Рекомбинантный иммунотоксин, нацеленный на мезотелин
JP2021106617A5 (hr)
JP2018502572A5 (hr)
RU2016119152A (ru) Стабильные и растворимые антитела, ингибирующие vegf
Chan et al. Comparison of the efficiency of antibody selection from semi-synthetic scFv and non-immune Fab phage display libraries against protein targets for rapid development of diagnostic immunoassays
JP7138046B2 (ja) 二特異性抗体基幹
JP2018521638A5 (hr)
JP2005535301A5 (hr)
JP2010502183A5 (hr)
RU2013124808A (ru) Новое антитело против dr5
JP2014515921A5 (hr)
JP2014158485A5 (hr)
JP2020524510A5 (hr)
FI3665192T3 (fi) Muunneltuja transferriinireseptoria sitovia polypeptidejä
EP2668206A1 (en) Engineering of immunoglobulin domains
JP2013535191A5 (hr)
JP2017509323A5 (hr)
JP2011505810A5 (hr)